Gliclazide

Gliclazide (S1702) is a whole-cell beta-cell ATP-sensitive potassium currents blocker with an IC50 of 184 nM. Gliclazide is used as an antidiabetic[1].

Product Specifications

CAS Number

[21187-98-4]

Product Name Alternative

S1702; SE1702

UNSPSC

12352005

Hazard Statement

H302

Target

Potassium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/gliclazide.html

Purity

99.58

Solubility

DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

Smiles

O=S(C1=CC=C(C)C=C1)(NC(NN2CC3C(CCC3)C2)=O)=O

Molecular Formula

C15H21N3O3S

Molecular Weight

323.41

Precautions

H302

References & Citations

[1]Shimoyama, T., et al., Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. Metabolism, 2006. 55 (6) : p. 722-30.|[2]Lawrence, C.L., et al., Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia, 2001. 44 (8) : p. 1019-25.